GRAIL, Inc. (GRAL): Capital Expenditures
$909.0K
Year ended 2025-12-31
$1.41M
Trailing 12 months to 2026-06-30
-65.9%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $909.0K | -82.5% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $5.21M | -59.6% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $12.89M | n/a | 2026-03-12, From 2023-01-01 |
| 2023-01-01, Fiscal 2022 | $22.86M | n/a | 2025-03-05, From 2022-01-03 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| GRAIL, Inc. (GRAL) | 2025-12-31 | $909.0K | -82.5% |
| Biodesix Inc (BDSX) | 2025-12-31 | $259.0K | -92.0% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $8.88M | +64.4% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $4.50M | +181.0% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $22.57M | -44.0% |
| Exagen Inc. (XGN) | 2025-12-31 | $641.0K | +24.5% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $36.02M | +27.2% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $9.68M | -14.3% |
| American Shared Hospital Services (AMS) | 2025-12-31 | $7.63M | -3.8% |
Compare GRAL, BDSX, BLLN, PSNL side by side · Screen every company in Services-Medical Laboratories ↗